Literature DB >> 10937470

Therapy of Crohn's disease in childhood.

R M Beattie1.   

Abstract

Crohn's disease in childhood is a chronic relapsing condition with a high morbidity. Growth failure is common. The aim of therapy is to induce and then maintain disease remission and thereby promote well-being and normal growth and development. Enteral nutrition (either polymeric or elemental) is effective and used as initial therapy. This is employed as sole therapy over a 6- to 8-week period followed by a period of controlled food reintroduction. The relapse rate is high and further courses of enteral nutrition or alternative therapies are frequently required. Corticosteroids are also effective as initial therapy and are required in difficult cases but there are problems with their long term use, particularly their adverse effects on growth. Many patients develop either corticosteroid-dependent or corticosteroid-resistant disease. In this instance, additional immunosuppression, such as azathioprine, can be used. Surgery is required for those patients with disease resistant to medical therapy and this will result in remission; however, the relapse rate with surgery is high. There are many areas for future research. Very little is known about why enteral nutrition works, how long it should be given or its role as maintenance therapy. Newer immunosuppressive strategies based on cytokine modulation may be helpful in children once more experience is gained from their use in adults.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10937470     DOI: 10.2165/00128072-200002030-00004

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  78 in total

1.  Indications for investigation of chronic gastrointestinal symptoms.

Authors:  R M Beattie; J A Walker-Smith; S H Murch
Journal:  Arch Dis Child       Date:  1995-10       Impact factor: 3.791

2.  Chronic inflammatory bowel disease in childhood.

Authors:  S K Chong; C Bartram; C A Campbell; C B Williams; A J Blackshaw; J A Walker-Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-09

3.  Inflammatory bowel disease and predisposition to osteopenia.

Authors:  F J Cowan; J T Warner; F D Dunstan; W D Evans; J W Gregory; H R Jenkins
Journal:  Arch Dis Child       Date:  1997-04       Impact factor: 3.791

4.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

5.  Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.

Authors:  L J Egan; W J Sandborn; W J Tremaine
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

6.  Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease.

Authors:  R M Beattie; E J Schiffrin; A Donnet-Hughes; A C Huggett; P Domizio; T T MacDonald; J A Walker-Smith
Journal:  Aliment Pharmacol Ther       Date:  1994-12       Impact factor: 8.171

7.  Assessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease.

Authors:  C Axelsson; S Jarnum
Journal:  Scand J Gastroenterol       Date:  1977       Impact factor: 2.423

8.  The technetium white cell scan as an initial imaging investigation for evaluating suspected childhood inflammatory bowel disease.

Authors:  D B Shah; M Cosgrove; J I Rees; H R Jenkins
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-11       Impact factor: 2.839

9.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Authors:  Y Bouhnik; M Lémann; J Y Mary; G Scemama; R Taï; C Matuchansky; R Modigliani; J C Rambaud
Journal:  Lancet       Date:  1996-01-27       Impact factor: 79.321

10.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.

Authors:  W R Connell; M A Kamm; M Dickson; A M Balkwill; J K Ritchie; J E Lennard-Jones
Journal:  Lancet       Date:  1994-05-21       Impact factor: 79.321

View more
  1 in total

1.  Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.

Authors:  C Romano; S Cucchiara; A Barabino; V Annese; C Sferlazzas
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.